These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35475465)

  • 41. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
    Kleiner DE; Makhlouf HR
    Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.
    Charlton M; Krishnan A; Viker K; Sanderson S; Cazanave S; McConico A; Masuoko H; Gores G
    Am J Physiol Gastrointest Liver Physiol; 2011 Nov; 301(5):G825-34. PubMed ID: 21836057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comprehensive characterization of metabolic, inflammatory and fibrotic changes in a mouse model of diet-derived nonalcoholic steatohepatitis.
    Kim MB; Lee Y; Bae M; Kang H; Pham TX; Hu S; Lee JY; Park YK
    J Nutr Biochem; 2020 Nov; 85():108463. PubMed ID: 32891893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models.
    Sanches SC; Ramalho LN; Augusto MJ; da Silva DM; Ramalho FS
    Biomed Res Int; 2015; 2015():574832. PubMed ID: 26064924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.
    Mells JE; Fu PP; Kumar P; Smith T; Karpen SJ; Anania FA
    J Nutr Biochem; 2015 Mar; 26(3):285-92. PubMed ID: 25577467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
    Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
    Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
    Liangpunsakul S; Chalasani N
    Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity.
    Xin SL; Yu YY
    Dig Liver Dis; 2022 Aug; 54(8):1021-1029. PubMed ID: 35288065
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dietary fat, cholesterol, and cholic acid affect the histopathologic severity of nonalcoholic steatohepatitis in Sprague-Dawley rats.
    Fukuda A; Sasao M; Asakawa E; Narita S; Hisano M; Suruga K; Ichimura M; Tsuneyama K; Tanaka K; Omagari K
    Pathol Res Pract; 2019 Nov; 215(11):152599. PubMed ID: 31564568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast-Enhanced MRI.
    Wu Z; Cheng ZL; Yi ZL; Xie MW; Zeng H; Lu LJ; Xu X; Shen J
    J Magn Reson Imaging; 2017 May; 45(5):1485-1493. PubMed ID: 27606822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.